Cerevel Therapeutics
Cerevel Therapeutics sponsors 21 registered US clinical trials on ClinicalTrials.gov, none currently recruiting, and 20 completed. 0 of these trials are in Phase 3-4 (later-stage) and 21 in Phase 1-2 (earlier-stage). The most-studied condition in this pipeline is Healthy Participants, with 2 trials.
Trial Pipeline
21 total, page 1 of 1
A Trial to Assess the Absorption, Metabolism, Excretion, and Mass Balance of [14C]-Darigabat After a Single Oral Dose in Healthy Male Participants
NCT06435923
A Trial to Evaluate the Effect of Esomeprazole on the Pharmacokinetics of Emraclidine in Healthy Adult Participants
NCT06366243
A Study to Assess Mass Balance, Pharmacokinetics, Metabolism, and Excretion of Emraclidine in Healthy Adult Male Participants
NCT06301971
A Trial to Evaluate the Effects of Itraconazole and Carbamazepine on the Pharmacokinetics of Emraclidine and of Emraclidine on the Pharmacokinetics of Metformin in Healthy Adult Participants
NCT05965219
A Study Evaluating the Pharmacokinetics and Relative Bioavailability of Emraclidine Immediate-Release Tablets in Healthy Adult Participants
NCT05933187
The Effect of Food on the Pharmacokinetics (PK) of Emraclidine in Healthy Adult Participants
NCT05915546
Open-label Trial to Evaluate the Effect Carbamazepine on Darigabat Pharmacokinetics in Healthy Adult Participants
NCT05824143
Positron Emission Tomography (PET) Trial to Evaluate Target Occupancy of CVL-354 at Kappa and Mu Opioid Receptors in Brain Following Oral Dosing
NCT05547542
Multiple-dose Trial to Determine the Clinical Bioequivalence Between Tavapadon Tablets in Participants With Parkinson's Disease
NCT05610189
Study to Evaluate the Effects of Cytochrome P450 (CYP) 3A4 Inducer Carbamazepine on Tavapadon Pharmacokinetics in Healthy Adult Participants
NCT05581823
To Evaluate Pharmacokinetics (PK) and Safety of Tavapadon in Participants With Severe Renal Impairment Compared to Participants With Normal Renal Function
NCT05404542
To Evaluate the Pharmacokinetics (PK) and Safety of Tavapadon in Participants With Mild and Moderate Hepatic Impairment Compared to Participants With Normal Hepatic Function
NCT05404529
Trial to Study the Effect of CVL-231 on 24-Hour Ambulatory Blood Pressure in Participants With Schizophrenia
NCT05245539
Pharmacokinetics of CVL-231 Following Single Oral Administration of Modified- and Immediate-release Formulations in Fasted and Fed Healthy Participants
NCT05106309
Relative Bioavailability and Food Effect Following Single Oral Dose of Darigabat Tablet Formulations in Healthy Participants
NCT05123079
A Single and Multiple Ascending Dose Trial of CVL-354 in Healthy Participants
NCT05138653
PET Trial to Evaluate Target Occupancy of CVL-231 on Brain Receptors Following Oral Dosing
NCT04787302
An Open-label Trial to Evaluate Mass Balance of Tavapadon at Steady State in Healthy Subjects
NCT04241393
A 2-Part Trial of CVL-751 in Subjects With Parkinson's Disease
NCT04295642
A Single Ascending Dose Trial of CVL-936 in Healthy Subjects
NCT04232878
A Multiple Ascending Dose Trial of CVL-231 in Subjects With Schizophrenia
NCT04136873
Phase Distribution
| Phase | Trial count |
|---|---|
| Phase 1 | 21 |
Therapeutic Areas
What the Pipeline for Cerevel Therapeutics Shows
According to the ClinicalTrials.gov registry, Cerevel Therapeutics is linked to 21 US clinical trials across every stage of research activity. Of those, 0 studies are currently recruiting, about 0% of the sponsor's indexed portfolio, and 20 are already marked complete, representing roughly 95% of the total.
The phase mix for Cerevel Therapeutics reports 0 late-stage studies (Phase 3 and Phase 4 combined) and 21 earlier-phase studies (Phase 1 and Phase 2).
The top therapeutic focus area indexed for Cerevel Therapeutics is Healthy Participants with 2 linked trials, and 5 other condition areas appear in the top list above.
How to read these pipeline numbers
Recruiting share is one of the more practical signals here: it reflects how much of a sponsor's research is presently open to new participants, while the completed share indicates the depth of finished work that has already contributed registry results. Both counts come directly from the public ClinicalTrials.gov dataset and are refreshed on the registry side; this page mirrors the latest data pull without altering it.
A portfolio weighted toward Phase 3 usually reflects an organization advancing candidates toward regulatory review, where the research centers on comparative efficacy and broader safety across larger populations. A heavier Phase 1 and Phase 2 tilt generally indicates exploratory work, safety, dosing, and early signal detection, and is common among research-forward sponsors that seed many early programs. Phase 4 entries, when present, track interventions already in real-world use and typically focus on long-term safety, effectiveness across subgroups, or formulation comparisons.
That distribution is a quick read of where the organization concentrates its research attention; it does not imply product availability, market share, or any clinical endorsement. All numbers on this page come from ClinicalTrials.gov maintained by the National Library of Medicine, and counts can shift as new studies are registered or existing ones update their status. This information is provided for reference and educational purposes only, not as medical, investment, or regulatory advice, verify current details directly with ClinicalTrials.gov before relying on any figure here.
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page aggregates every registered trial from this sponsor, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.